CN111304291B - DNA extraction reagent, kit and extraction method - Google Patents
DNA extraction reagent, kit and extraction method Download PDFInfo
- Publication number
- CN111304291B CN111304291B CN202010235846.9A CN202010235846A CN111304291B CN 111304291 B CN111304291 B CN 111304291B CN 202010235846 A CN202010235846 A CN 202010235846A CN 111304291 B CN111304291 B CN 111304291B
- Authority
- CN
- China
- Prior art keywords
- dna
- concentration
- dna extraction
- centrifuging
- rinsing liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000007400 DNA extraction Methods 0.000 title claims abstract description 37
- 238000000605 extraction Methods 0.000 title claims abstract description 32
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 claims abstract description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 18
- 239000000243 solution Substances 0.000 claims abstract description 14
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 230000009089 cytolysis Effects 0.000 claims abstract description 13
- 239000011780 sodium chloride Substances 0.000 claims abstract description 9
- 239000003480 eluent Substances 0.000 claims abstract description 7
- 239000012487 rinsing solution Substances 0.000 claims abstract description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 5
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims abstract description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims abstract description 5
- 239000007788 liquid Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 239000000706 filtrate Substances 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 8
- 239000011324 bead Substances 0.000 claims description 7
- 239000006166 lysate Substances 0.000 claims description 5
- 229960000789 guanidine hydrochloride Drugs 0.000 claims description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 claims description 4
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 4
- 239000011521 glass Substances 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- 210000002700 urine Anatomy 0.000 claims description 2
- 238000001514 detection method Methods 0.000 abstract description 27
- 238000011529 RT qPCR Methods 0.000 abstract description 14
- 108020004707 nucleic acids Proteins 0.000 abstract description 10
- 102000039446 nucleic acids Human genes 0.000 abstract description 10
- 150000007523 nucleic acids Chemical class 0.000 abstract description 10
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 abstract 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 25
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 101710102690 Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 9
- 238000005119 centrifugation Methods 0.000 description 9
- 238000001179 sorption measurement Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 208000003174 Brain Neoplasms Diseases 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 108010039627 Aprotinin Proteins 0.000 description 4
- 229960004405 aprotinin Drugs 0.000 description 4
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical group C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 101001042041 Bos taurus Isocitrate dehydrogenase [NAD] subunit beta, mitochondrial Proteins 0.000 description 3
- 101000960234 Homo sapiens Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 101000960235 Dictyostelium discoideum Isocitrate dehydrogenase [NADP] cytoplasmic Proteins 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000045 chemical toxicity Toxicity 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 238000007886 magnetic bead extraction Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000009598 prenatal testing Methods 0.000 description 1
- 108010071967 protein K Proteins 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a DNA extraction reagent, a kit and an extraction method. The invention firstly provides a DNA extraction reagent, which comprises lysis solution, rinsing solution 1, rinsing solution 2 and eluent, wherein the lysis solution comprises guanidine isothiocyanate, Tris-HCl, EDTA, NaCl, SDS and protease inhibitor. The invention further provides a kit containing the DNA extraction reagent and a method for extracting DNA by using the DNA extraction reagent or the kit. The DNA extraction method is rapid, simple and convenient, is beneficial to the crushing of fresh tissues or frozen tissues, is particularly suitable for rapid operation in operations, has low relative extraction cost and high quality of extracted nucleic acid, and can meet the requirements of detection such as qPCR, NGS, SNP typing and the like.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a DNA extraction reagent, a kit and an extraction method.
Background
Nucleic acid amplification and detection techniques are widely used, particularly in the fields of disease diagnosis, detection of microorganisms and pathogenic agents, and the like. In the field of disease diagnosis, with the advent of the era of precision medicine, genetic testing technology is a necessary technological means in the aspects of genetic disease diagnosis, prenatal testing, molecular typing, personalized medicine application and the like. In diagnostic procedures, nucleic acid analysis has many advantages over traditional methods, such as enzymatic or antibody analysis, with high sensitivity, flexibility and short time.
In the diagnostic process, nucleic acid extraction and purification are the basis of nucleic acid detection, and the quality of the extracted and purified nucleic acid has important influence on the accuracy of the detection result. At present, the commonly used extraction method for releasing biological nucleic acid comprises: alkaline lysis, phenol extraction, silica gel membrane centrifugation column, magnetic bead method, etc. Wherein, the alkaline cracking method generally adopts corrosive sodium hydroxide for modification and then uses acid for neutralization and precipitation; the phenol extraction method has complex steps, and adopts organic solvents such as phenol, chloroform and the like for extraction, so that the chemical toxicity is high; the magnetic bead method adopts a magnetic bead adsorption and solvent elution method to extract DNA, a magnetic sleeve and a magnet are required to be used for adsorption in the operation process, the operation flux is limited, and the operation is usually completed by means of a full-automatic magnetic bead extraction instrument; the silica gel membrane centrifugal column adopts a macromolecule resin membrane to intercept and purify DNA, and the whole process needs to be repeatedly centrifuged at high speed and the tube is replaced, so that the time is long.
The major bottleneck in the widespread adoption of molecular diagnostics in medical laboratories today is the requirement to purify nucleic acids from samples: the commercial biological nucleic acid DNA release extraction kit generally adopts a silica gel membrane centrifugal column and a magnetic bead method, has complex operation process and long time consumption, needs at least 1.5 hours, is not beneficial to rapid detection, and particularly detection in disease (cancer) treatment operations, so that a nucleic acid extraction method which is simple, convenient, rapid and high in quality is urgently needed to be developed.
Disclosure of Invention
The technical problem to be solved by the invention is how to find a method for simply, conveniently and quickly extracting high-quality DNA.
In order to solve the technical problems, the invention firstly provides a DNA extraction reagent.
The DNA extraction reagent comprises a lysis solution, wherein the lysis solution comprises guanidinium isothiocyanate with the concentration of 4-6mol/L, Tris-HCl with the concentration of 40-60mmol/L, EDTA with the concentration of 5-20mmol/L, NaCl with the concentration of 120-160mmol/L, Triton X-100 with the volume percentage of 1-1.3%, SDS with the mass percentage of 0.05-0.15% and a protease inhibitor with the concentration of 3-8 mu g/ml.
The volume percentage content is the volume percentage content of solute in the solution, namely the volume percentage content of TritonX-100 in the lysis solution is 1-1.3%; the mass percentage is the mass content of the solute in the solution, namely the mass content of SDS in the lysate is 0.05-0.15%.
Optionally, the concentration of guanidinium isothiocyanate is 4mol/L, 5mol/L or 6mol/L, the concentration of Tris-HCl is 40mmol/L, 45mmol/L, 50mmol/L, 55mmol/L or 60mmol/L, the concentration of EDTA is 5mmol/L, 8mmol/L, 10mmol/L, 12mmol/L, 15mmol/L, 17mmol/L or 20mmol/L, the concentration of NaCl is 120mmol/L, 130mmol/L, 140mmol/L, 150mmol/L or 160mmol/L, the volume percentage of triton x-100 is 1%, 1.1%, 1.2% or 1.3%, and the mass percentage of SDS is 0.05%, 0.1% or 0.15%; the concentration of the protease inhibitor is 3 mug/ml, 5 mug/ml or 8 mug/ml.
Wherein, optionally, the protease inhibitor is Aprotinin (Aprotinin).
The lysis solution also comprises a solvent, wherein the solvent is water.
The DNA extraction reagent also comprises a rinsing liquid 1 and a rinsing liquid 2;
wherein,
the pH values of the rinsing liquid 1 and the rinsing liquid 2 are both 6-8,
the rinsing liquid 1 comprises guanidine hydrochloride with the concentration of 6-8mol/L, Tris-HCl with the concentration of 20-30mmol/L and ethanol with the volume percentage content of 45-55%;
the rinsing liquid 2 comprises NaCl with the concentration of 100-200mmol/L, Tris-HCl with the concentration of 15-25mmol/L and ethanol with the volume percentage of 70-80%.
In particular, it is possible, alternatively,
in the rinsing liquid 1, the concentration of the guanidine hydrochloride is 6mol/L, 7mol/L or 8mol/L, the concentration of the Tris-HCl is 20mmol/L, 25mmol/L or 30mmol/L, and the volume percentage of the ethanol is 45%, 50% or 55%;
in the rinsing liquid 2, the concentration of NaCl is 100mmol/L, 150mmol/L or 200mmol/L, the concentration of Tris-HCl is 15mmol/L, 20mmol/L or 25mmol/L, and the volume percentage content of ethanol is 70%, 75% or 80%.
The DNA extraction reagent also comprises an eluent which is water without nuclease.
The invention also provides a DNA extraction reagent which consists of the lysate, the rinsing solution 1, the rinsing solution 2 and the eluent.
The invention further provides a DNA extraction kit containing the DNA extraction reagent.
The kit of the invention comprises the DNA extraction reagent and a centrifugal column.
Specifically, the centrifugal column is a silica gel adsorption membrane centrifugal column.
The application of the DNA extraction reagent or the DNA extraction kit in DNA extraction is also within the protection scope of the invention.
The invention further provides a method for extracting DNA.
The method for extracting the DNA comprises the following steps:
adding the lysis solution into an extracted sample for crushing, centrifuging after crushing, and taking supernatant;
transferring the supernatant to a centrifugal column and then centrifuging;
adding the rinsing liquid 1 into a centrifugal column, centrifuging, and removing filtrate;
adding the rinsing liquid 2 into a centrifugal column, centrifuging, and removing the filtrate;
and adding the eluent into a centrifugal column, centrifuging, and collecting filtrate to obtain the DNA.
In the above extraction method, the centrifugation after the disruption is a centrifugation immediately after the disruption.
In the above extraction method, the sample may be tissue, saliva, urine or blood (such as leukocyte).
In particular, the tissue may be frozen tissue or fresh tissue.
In the extraction method, the mass-volume ratio of the extracted sample to the lysate is 1mg:20-50 muL.
Optionally, the extraction method specifically includes:
adding the lysis solution and glass beads into the extracted sample, crushing for 1min, centrifuging, and collecting supernatant; the centrifugation conditions were: the rotating speed is 14000rpm and the time is 1 min;
transferring the supernatant to a centrifugal column, centrifuging, and replacing a new collecting pipe; the centrifugation conditions were: the rotating speed is 14000rpm and the time is 15 s;
adding the rinsing liquid 1 into a centrifugal column, centrifuging, and replacing a new collecting pipe; the centrifugation conditions were: the rotating speed is 14000rpm and the time is 15 s;
adding the rinsing liquid 2 into a centrifugal column, centrifuging, and replacing a new collecting pipe; the centrifugation conditions were: the rotating speed is 14000rpm and the time is 15 s;
adding the eluent into a centrifugal column, centrifuging, and collecting filtrate to obtain DNA; the centrifugation conditions were: the rotation speed was 14000rpm and the time was 30 seconds.
The DNA extraction method is rapid, simple and convenient, is beneficial to the crushing of fresh tissues or frozen tissues, is particularly suitable for rapid operation in operations, has low relative extraction cost and high quality of extracted nucleic acid, and can meet the requirements of detection such as qPCR, NGS, SNP typing and the like.
Drawings
FIG. 1 shows the qPCR detection results of DNA obtained by Qiagen kit extraction method.
FIG. 2 shows the qPCR detection results of DNA obtained by the rapid extraction method.
FIG. 3 shows the qPCR detection results of DNA obtained by crude extraction method.
Fig. 4 shows the minimum detection limit of IDH 1.
Detailed Description
The following examples are given to facilitate a better understanding of the invention, but do not limit the invention. The experimental procedures used in the following examples are all conventional procedures unless otherwise specified. Materials, reagents and the like used in the following examples are commercially available unless otherwise specified.
Example 1 DNA extraction and qPCR detection of fresh brain tumor tissue
First, the rapid extraction method of DNA of the present application
1. Adding 600 μ L of lysis solution into 25mg of brain tumor tissue, adding glass beads, placing in a crusher, grinding and crushing for 1min, centrifuging at 14000rpm for 1min after crushing, transferring 500 μ L of supernatant into a centrifugal column, and centrifuging at 14000rpm for 15 s; this step required 3 min;
wherein the lysate comprises the following components in percentage by weight:
5mmol/L guanidinium isothiocyanate;
50mmol/L Tris-HCl;
10mmol/L EDTA;
150mmol/L NaCl;
0.1% (mass percent) SDS;
5 μ g/ml Aprotinin (Aprotinin);
1-1.3 percent of TritonX-100 by volume percentage.
2. Transferring the silica gel adsorption membrane centrifugal column into a new collecting tube, adding 500 mul of rinsing liquid 1, centrifuging at 14000rpm for 15s, and replacing the collecting tube; this step requires 30 s;
wherein, the rinsing liquid 1 (with pH of 6) comprises the following components in percentage by weight:
the concentration of guanidine hydrochloride is 6M;
20mmol/L Tris-HCl;
55 percent (volume percentage) of ethanol.
3. Adding 500 mul of rinsing liquid 2 into a silica gel adsorption film centrifugal column, centrifuging at 14000rpm for 15 s; this step requires 30 s;
wherein, the rinsing liquid 2 (with pH of 6) comprises the following components in percentage by weight:
200mmol/L NaCl;
20mmol/L Tris-HCl;
70% (volume percentage content) ethanol.
4. Transferring the column into a 1.5mL centrifugal tube, adding 50-100 μ l of nuclease-free water, centrifuging at 14000rpm for 30s, and collecting filtrate to obtain DNA for subsequent qPCR detection. This step required 1 min.
The total time required for this DNA extraction method was 5 minutes.
Second, general method for crude extraction of DNA
Grinding 25mg brain tumor tissue, adding 200 μ l Chelex extract, boiling for 1min, centrifuging at 12000rpm for 1min, collecting supernatant to obtain crude extract of DNA, and using for subsequent qPCR detection.
The time required for this crude DNA extraction method was 5 minutes.
Third, DNA extraction method using kit (Qiagen organism Co., Ltd., Cat. No. 69504)
1. Taking 25mg brain tumor tissue, cutting, adding 180. mu.l Buffer ATL, shaking thoroughly, mixing well, adding 20. mu.l Protein K, incubating at 56 deg.C until the tissue is completely digested, and clarifying the liquid, wherein the step needs 30 min.
2. Vortex for 15s, add 200. mu.l buffer AL, mix well, then add 200. mu.l absolute ethanol, mix well again to obtain a mixture, which takes 2 min.
3. The mixture was transferred to an adsorption column and centrifuged at 8000rpm for 1min, and the filtrate was discarded, which required 1.5min for this step.
4. The adsorption column was placed in a new collection tube, 500. mu.l Buffer AW1 was added, 14000rpm was centrifuged for 1min, and the filtrate was discarded, which required 1.5min for this step.
5. The adsorption column was placed in a new collection tube, 500. mu.l Buffer AW2 was added, the centrifugation was carried out at 14000rpm for 3min, and the filtrate was discarded, which required 3.5min for this step.
6. And (3) putting the adsorption column into a 1.5mL centrifuge tube, adding 200 mul of Buffer AE, incubating at room temperature for 1min, centrifuging at 8000rpm for 1min, and collecting filtrate to obtain DNA for subsequent qPCR detection, wherein the step needs 2.5 min.
The DNA extraction method requires at least 41 min.
Four, qPCR detection of IDH1 mutation
The DNA samples extracted in the first, second and third steps are all diluted to 10 ng/ul, 2 ul is added into 18 ul IDH 1R 132H PCR reaction mixed liquid to obtain 20 ul of reaction system for qPCR detection.
Wherein, in the mixed solution of IDH 1R 132H PCR reaction, the primer sequence of IDH 1R 132H is as follows: f: CTTACTTGATCCCCATAAGCATGCT (SEQ ID NO. 1); r: TTATTGCCAACATGACTTACTTGA (SEQ ID NO. 2); the IDH 1R 132H probe sequence is: FAM-ACATGACTTACTTGATCC-BHQ1, wherein the sequence of the internal reference upstream primer is as follows: GATAGGCACTGACTCTCTCTG, respectively; the sequence of the internal reference downstream primer is as follows: AGCATCAGGAGTGGACAGAT, respectively; the reference probe sequence is as follows: ROX-CTACCCTTGGACCCAGAGGTTCTTTGAG-BHQ 2.
The reaction mixture for IDH 1R 132H PCR was prepared by adding various substances to the reaction premix in the concentrations shown in Table 1. Wherein, the reaction PCR premix comprises: DNA polymerase, Mg2+dNTPs and stabilizers. Such as: takara Premix Ex Taq (Probe qPCR).
TABLE 1 concentrations of the respective substances in the qPCR reaction mixture
The PCR reaction conditions are shown in Table 2.
TABLE 2 PCR reaction conditions
And (4) judging a result:
BIO-Rad: setting the signal baseline as 200RFU, if the difference between the Ct values of the FAM signal and the ROX signal is less than or equal to 10, the detected sample is positive, otherwise, the detected sample is negative.
The detection results are shown in fig. 1, 2 and 3, and the results show that the qPCR detection results of the DNA obtained by the rapid extraction method of the invention and the DNA kit extraction method are consistent, and the crude extraction method results show that the internal reference amplification is normal, but the IDH1 mutation cannot be detected.
Example 2 DNA extraction and IDH 1R 132H mutation Point detection of frozen brain tumor tissue
The genomic DNA of 38 cases of frozen brain tumor tissues was extracted by the rapid DNA extraction method and DNA kit (Qiagen organism Co., Ltd., cat number 69504) extraction method of example 1 of the present invention, and IDH 1R 132H mutation point detection was performed.
The extracted sample was diluted to 10 ng/. mu.l, and 2. mu.l was taken for detection. The detection system and reaction conditions are shown in example 1.
And (4) judging a result:
BIO-Rad: setting the signal baseline as 200RFU, if the difference between the Ct values of the FAM signal and the ROX signal is less than or equal to 10, the detected sample is positive, otherwise, the detected sample is negative.
The detection results are shown in fig. 4 and table 3, the lowest detection limit of IDH1 can reach 1%, and the rapid extraction method of the invention is consistent with the detection result of the mutation point of IDH 1R 132H of the DNA obtained by the extraction method of the DNA kit.
TABLE 3 IDH 1R 132H mutation Point test results
The present invention has been described in detail above. It will be apparent to those skilled in the art that the invention can be practiced in a wide range of equivalent parameters, concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation. While the invention has been described with reference to specific embodiments, it will be appreciated that the invention can be further modified. In general, this application is intended to cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains. The use of some of the essential features is possible within the scope of the claims attached below.
SEQUENCE LISTING
<110> Beijing Panshengzi Gene science and technology Co., Ltd
<120> GNCFY200071
<130> DNA extraction reagent, kit and extraction method
<160> 2
<170> PatentIn version 3.5
<210> 1
<211> 25
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
cttacttgat ccccataagc atgct 25
<210> 2
<211> 24
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
ttattgccaa catgacttac ttga 24
Claims (8)
1. A DNA extraction reagent, characterized in that: the DNA extraction reagent consists of lysis solution, rinsing solution 1, rinsing solution 2 and eluent,
the lysis solution consists of guanidinium isothiocyanate with the concentration of 4-6mol/L, Tris-HCl with the concentration of 40-60mmol/L, EDTA with the concentration of 5-20mmol/L, NaCl with the concentration of 120-160mmol/L, TritonX-100 with the volume percentage content of 1-1.3%, SDS with the mass percentage of 0.05-0.15% and protease inhibitor with the concentration of 3-8 mu g/ml;
the pH values of the rinsing liquid 1 and the rinsing liquid 2 are both 6-8, and the rinsing liquid 1 consists of guanidine hydrochloride with the concentration of 6-8mol/L, Tris-HCl with the concentration of 20-30mmol/L and ethanol with the volume percentage content of 45-55%;
the rinsing liquid 2 consists of NaCl with the concentration of 100-200mmol/L, Tris-HCl with the concentration of 15-25mmol/L and ethanol with the volume percentage of 70-80%.
2. A DNA extraction kit, which is characterized in that: the DNA extraction kit comprises the DNA extraction reagent according to claim 1.
3. The DNA extraction kit according to claim 2, characterized in that: the DNA extraction kit further comprises a centrifugal column.
4. Use of the DNA extraction reagent of claim 1 or the DNA extraction kit of claim 2 or 3 for extracting DNA.
5. A method for extracting DNA, comprising the steps of:
adding the lysis solution in claim 1 into an extracted sample, adding glass beads, crushing the sample on a crusher, centrifuging the crushed sample, and taking supernatant;
transferring the supernatant to a centrifugal column and then centrifuging;
adding the rinsing liquid 1 in the claim 1 into a centrifugal column, centrifuging, and discarding the filtrate;
adding the rinsing liquid 2 in the claim 1 into a centrifugal column, centrifuging, and discarding the filtrate;
adding the eluent of claim 1 into a centrifugal column, centrifuging, and collecting the filtrate to obtain DNA.
6. The extraction method according to claim 5, characterized in that: centrifuging after crushing, namely centrifuging immediately after crushing;
or the mass volume ratio of the extracted sample to the lysate is 1mg:20-50 μ L.
7. The extraction method according to claim 5, characterized in that: the extracted sample is tissue, saliva, urine or blood.
8. The extraction method according to claim 7, characterized in that: the tissue is frozen tissue or fresh tissue.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010235846.9A CN111304291B (en) | 2020-03-30 | 2020-03-30 | DNA extraction reagent, kit and extraction method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010235846.9A CN111304291B (en) | 2020-03-30 | 2020-03-30 | DNA extraction reagent, kit and extraction method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111304291A CN111304291A (en) | 2020-06-19 |
CN111304291B true CN111304291B (en) | 2022-04-19 |
Family
ID=71153691
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010235846.9A Active CN111304291B (en) | 2020-03-30 | 2020-03-30 | DNA extraction reagent, kit and extraction method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111304291B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111996108A (en) * | 2020-09-03 | 2020-11-27 | 北京橡鑫生物科技有限公司 | Pipette tip, kit comprising pipette tip and DNA extraction method |
CN114350649A (en) * | 2021-12-02 | 2022-04-15 | 力因精准医疗产品(上海)有限公司 | Nucleic acid extraction kit and nucleic acid extraction method |
CN116410973B (en) * | 2023-06-09 | 2023-09-19 | 天根生化科技(北京)有限公司 | Genomic DNA extraction kit and genomic DNA extraction method |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101935645A (en) * | 2010-09-13 | 2011-01-05 | 原平皓(天津)生物技术有限公司 | Kit for extracting DNA from histiocytes and method thereof |
CN106906207A (en) * | 2017-04-19 | 2017-06-30 | 遵义医学院 | Rapid nucleic acid extraction kit and its application method |
CN108642048A (en) * | 2018-05-23 | 2018-10-12 | 山东宏济堂制药集团济南阿胶制品有限公司 | A kind of kit and extracting method can be applied to the high-throughput extraction genomic DNA from animal tissue |
CN108753767A (en) * | 2018-08-02 | 2018-11-06 | 广州奕昕生物科技有限公司 | A kind of Viral nucleic acid extraction reagent box and extracting method |
CN109182335A (en) * | 2018-10-17 | 2019-01-11 | 广州奕昕生物科技有限公司 | A kind of Viral nucleic acid extraction reagent box |
CN109694863A (en) * | 2019-02-28 | 2019-04-30 | 深圳市刚竹医疗科技有限公司 | Extracting method for the lysate of nucleic acid extraction, cleaning solution, nucleic acid extraction kit and nucleic acid |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2843202T3 (en) * | 2012-09-28 | 2021-07-16 | Cepheid | Methods for DNA and RNA Extraction from Paraffin-embedded Fixed Tissue Samples |
US10968443B2 (en) * | 2014-12-31 | 2021-04-06 | The Rockefeller University | Method of RNA isolation from clinical samples |
US9976136B2 (en) * | 2015-05-14 | 2018-05-22 | Longhorn Vaccines And Diagnostics, Llc | Rapid methods for the extraction of nucleic acids from biological samples |
-
2020
- 2020-03-30 CN CN202010235846.9A patent/CN111304291B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101935645A (en) * | 2010-09-13 | 2011-01-05 | 原平皓(天津)生物技术有限公司 | Kit for extracting DNA from histiocytes and method thereof |
CN106906207A (en) * | 2017-04-19 | 2017-06-30 | 遵义医学院 | Rapid nucleic acid extraction kit and its application method |
CN108642048A (en) * | 2018-05-23 | 2018-10-12 | 山东宏济堂制药集团济南阿胶制品有限公司 | A kind of kit and extracting method can be applied to the high-throughput extraction genomic DNA from animal tissue |
CN108753767A (en) * | 2018-08-02 | 2018-11-06 | 广州奕昕生物科技有限公司 | A kind of Viral nucleic acid extraction reagent box and extracting method |
CN109182335A (en) * | 2018-10-17 | 2019-01-11 | 广州奕昕生物科技有限公司 | A kind of Viral nucleic acid extraction reagent box |
CN109694863A (en) * | 2019-02-28 | 2019-04-30 | 深圳市刚竹医疗科技有限公司 | Extracting method for the lysate of nucleic acid extraction, cleaning solution, nucleic acid extraction kit and nucleic acid |
Also Published As
Publication number | Publication date |
---|---|
CN111304291A (en) | 2020-06-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111304291B (en) | DNA extraction reagent, kit and extraction method | |
EP3636769B1 (en) | Sample nucleic acid measurement test kit, reagent, and application thereof | |
EP3792364A1 (en) | Method for detecting nucleic acid based on prokaryotic argonaute protein and application thereof | |
US20080213870A1 (en) | Methods for obtaining modified DNA from a biological specimen | |
US10161005B2 (en) | Method for detecting telomerase via washing-free anchored-extension and telomeric-binding amplification, and kit | |
JP4471659B2 (en) | Direct nucleic acid amplification method | |
CN109913445B (en) | One-step washing magnetic bead method blood DNA extraction kit | |
CN113186249B (en) | Kit for rapidly extracting viral nucleic acid and application method thereof | |
CN113637668A (en) | Kit for simultaneously extracting pathogenic bacteria DNA of blood plasma and blood cells and application thereof | |
CN111057791A (en) | Kit for detecting HBV pgRNA in blood | |
CN115896316A (en) | Tuberculosis detection method | |
US20210207125A1 (en) | Method of isolating nucleic acids for long sequencing reads | |
CA2297547C (en) | An improved method for preparing dna from serum and plasma | |
CN112063615A (en) | Genome DNA extracting solution, genome DNA extracting method and application thereof | |
CN112760420A (en) | Primer, probe and kit for detecting new coronavirus SARS-CoV-2 | |
CN111172319A (en) | Primer pair for detecting porcine epidemic diarrhea virus, kit and application thereof | |
CN112094860A (en) | CTCF-ETO2 blood disease fusion gene and detection primer and application thereof | |
WO2012043183A1 (en) | Method for synthesizing target nucleic acid in feces | |
CN111996239A (en) | Primers and probes for detecting acinetobacter baumannii and detection method thereof | |
CN112626204B (en) | Primers and method for detecting HLA-B1502 typing useful for guiding administration of carbamazepine | |
CN112094927B (en) | Primer group, detection reagent and detection kit for identifying nucleic acids of rhesus monkey and human | |
CN114517196A (en) | Extraction method and application of plasma free miRNA | |
Mu et al. | Simultaneous Extraction of Bone Marrow RNA and DNA from Patients with Hematologic Diseases Using a Combined Magnetic Bead Method within 1 Hour | |
CN113943804A (en) | Application of FGFR3 gene mutation detection in bladder cancer diagnosis and kit | |
CN103866045B (en) | HAV detection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |